CN114437033A - Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt - Google Patents

Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt Download PDF

Info

Publication number
CN114437033A
CN114437033A CN202011189484.0A CN202011189484A CN114437033A CN 114437033 A CN114437033 A CN 114437033A CN 202011189484 A CN202011189484 A CN 202011189484A CN 114437033 A CN114437033 A CN 114437033A
Authority
CN
China
Prior art keywords
yloxy
methyl
isopropionylpyrrolidine
nitroquinolin
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011189484.0A
Other languages
Chinese (zh)
Inventor
吴亮
邓一军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yahong Pharmaceutical Technology Co ltd
Jiangsu Yahong Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Yahong Pharmaceutical Technology Co ltd
Jiangsu Yahong Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yahong Pharmaceutical Technology Co ltd, Jiangsu Yahong Pharmaceutical Technology Co ltd filed Critical Shanghai Yahong Pharmaceutical Technology Co ltd
Priority to CN202011189484.0A priority Critical patent/CN114437033A/en
Publication of CN114437033A publication Critical patent/CN114437033A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a salt of a nitroxoline prodrug, a pharmaceutical composition containing the salt, a preparation method and application of the salt. The salt of the nitroxoline prodrug is the hydrochloride of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate. The hydrochloride has solubility far higher than that of free (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate and other salts, such as hydrobromide, methanesulfonate, bisulfate, so that the hydrochloride is easier to absorb and has higher bioavailability, and is more favorable for developing medicines suitable for human bodies.

Description

Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt
Technical Field
The invention relates to a salt of a nitroxoline prodrug, a pharmaceutical composition containing the salt, a preparation method and application of the salt.
Background
Nitroxoline, the british name Nitroxoline, the chemical name 5-nitro-8-hydroxyquinoline, was developed in the sixties as an oral antibiotic drug, mainly for urinary infections, with a safer history of use, and was later replaced by the discovery and use of new antibiotics.
In recent years, new researches show that the nitroxoline can simultaneously inhibit methionine aminopeptidase MetAP2 and a sirtuin 2-related enzyme SIRT1 in vascular endothelial cells to play a synergistic inhibition effect on tumor angiogenesis and simultaneously inhibit the proliferation of tumor cells. Thus, nitroxoline has been newly developed for the treatment of tumors including bladder cancer.
The prodrug is a compound obtained by chemically modifying an active drug, and is converted into the original drug by the action of an enzyme in vivo to exert the drug effect. The prodrug has wide application in drug research and development, is a modification method of drugs, can overcome various adverse characteristics and properties, and mainly can bring the following advantages: increase drug solubility, improve drug absorption and distribution, increase drug stability, reduce toxicity or adverse reactions, prolong drug action time, eliminate drug unsuitable properties, and the like.
The prior art has reported on nitroxoline prodrugs, however, there is no report on salts of nitroxoline prodrugs.
Disclosure of Invention
In order to solve the technical problem that no salt of a nitroxoline prodrug exists in the prior art, the invention provides a salt of a nitroxoline prodrug, a pharmaceutical composition containing the salt, a preparation method and application of the salt.
The invention solves the technical problems through the following technical scheme:
the present invention provides a hydrochloride salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate.
In some preferred embodiments, the molar ratio of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate to HCl is from 0.5:1 to 1.5: 1.
In some preferred embodiments, the molar ratio of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate to HCl is 1:1, i.e.
Figure BDA0002752340380000021
The present invention also provides a method for preparing the hydrochloride of the aforementioned (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate, which comprises the steps of:
reacting the mixture of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate and organic solvent with a solution containing hydrochloric acid, and carrying out solid-liquid separation to obtain the compound.
In some preferred above processes, the organic solvent is selected from one or more of tetrahydrofuran, methanol, ethanol, n-propanol, isopropanol, acetone and ethyl acetate, preferably tetrahydrofuran.
In some preferred above processes, the solvent in the hydrochloric acid-containing solution is selected from one or more of ethyl acetate, water, methanol, ethanol, n-propanol, isopropanol and acetone, preferably ethyl acetate.
In some preferred above processes, the equivalent ratio of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate to hydrogen chloride in the hydrochloric acid-containing solution is from 1:5 to 5:1, preferably from 1:1.5 to 1:3, more preferably from 1:1.5 to 1:2.5, even more preferably 1:2.
In some preferred above-mentioned processes, the temperature of the reaction is 10-30 ℃, preferably 20-30 ℃, e.g. 25 ℃.
In some preferred above-mentioned methods, the reaction time is 10min to 3h, preferably 10 to 60min, more preferably 25 to 35min, still more preferably 30 min.
In some preferred above processes, the solid-liquid separation is filtration.
The invention also provides a pharmaceutical composition, which comprises the hydrochloride of the (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate and a pharmaceutically acceptable carrier.
The pharmaceutical composition can be prepared into tablets, pills, powder, granules, capsules or emulsions, and can also be prepared into quick-release preparations or sustained-release preparations.
The pharmaceutical compositions of the present invention may be used for various routes of administration, such as oral or parenteral administration.
The invention also provides application of the hydrochloride of the (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate or the pharmaceutical composition in preparing anti-infective and/or anti-tumor drugs.
Wherein the infection is preferably a urinary tract infection.
Wherein the tumor is preferably selected from the group consisting of bladder cancer, prostate cancer and renal cancer.
The invention also provides a hydrochloride of the aforementioned (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate or a pharmaceutical composition of the aforementioned, for use against infection and/or tumor.
Wherein the infection is preferably a urinary tract infection.
Wherein the tumor is preferably selected from the group consisting of bladder cancer, prostate cancer and renal cancer.
The present invention also provides a method of treating an infection and/or tumor comprising administering to a patient in need thereof a therapeutically effective amount of the hydrochloride salt of the aforementioned (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate or the aforementioned pharmaceutical composition.
Wherein the infection is preferably a urinary tract infection.
Wherein the tumor is preferably selected from the group consisting of bladder cancer, prostate cancer and renal cancer.
It will be understood by those skilled in the art that the optimum dosage and interval will depend upon the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimum may be determined by conventional techniques. It will also be appreciated by those skilled in the art that the optimal course of treatment, i.e. the number of doses of active ingredient administered per day over a given period of time, can be determined by those skilled in the art using routine tests to determine the course of treatment.
Compared with the prior art, the technical scheme of the invention has the following advantages: the hydrochloride of the (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate has much higher solubility than free (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate and other salts, such as hydrobromide, methanesulfonate, bisulfate, so that the hydrochloride is easier to absorb and has higher bioavailability, and is more beneficial to developing medicaments suitable for human bodies.
Detailed Description
Terms not defined herein have meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. For the terms defined herein, they have the meanings set forth in the specification.
The term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable excipient, such as one or more of a binder, filler, disintegrant, and lubricant in a tablet, for delivering the hydrochloride salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate herein to a subject; semisolid formulations include the base portion of ointments and creams; one or more of preservatives, antioxidants, flavoring agents, fragrances, cosolvents, emulsifiers, solubilizers, tonicity adjusting agents and colorants in the liquid formulation.
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions. Known reagents, solvents, materials in the examples can be synthesized using or according to methods known in the art, or are commercially available.
Hereinafter, the purity analysis method is as follows: using a Kinetex EVO C18(50 x 4.6mm, 5 μm,
Figure BDA0002752340380000042
) And (3) carrying out gradient elution by using acetonitrile-water as a mobile phase on a chromatographic column, wherein the flow rate is 1.5mL/min, and the detection wavelength is 220 nm. Determination of MS Using an LC (Agilent 1260Infinity II)/MS (G6125B single quadrupole) mass spectrometer (manufacturer: Agilent) (Photodiode Array Detector). The structure of the compound is determined by hydrogen spectrum, and the model of the device is WNMR-I-400 MHz.
Hereinafter, compound 1 is (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate, prepared according to the method disclosed in example 20 of patent application publication No. WO2020/063824A 1.
Example 1: synthesis of hydrochloride of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate (Compound 2)
Figure BDA0002752340380000041
(S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionyl-pyrrolidine-2-carboxylate (compound 1) (200mg, 0.517mmol, 1eq) was dissolved in 5mL of THF, HCl/ethyl acetate solution (1.02mL, 1.02mmol, 2.0eq) was added, and the mixture was stirred at 25 ℃ for 30min to precipitate a solid, which was filtered and the cake was dried to constant weight, yielding 180mg of (S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionyl-pyrrolidine-2-carboxylate hydrochloride (compound 2) as a yellow solid with a purity of 99% in 82.5% yield.
Molecular weight: m + H+＝388.2(ESI)。
1H-NMR(400MHz,DMSO-d6):δ：9.10(d,J＝2.8Hz,1H),9.07(d,J＝8.4Hz,1H),8.56(d,J＝8.8Hz,1H),7.90(dd,J＝4.0Hz,8.8Hz,1H),7.58(d,J＝8.8Hz,1H),6.21(d,J＝6.4Hz,1H),6.17(d,J＝6.4Hz,1H),4.36-4.33(m,1H),3.58-3.55(m,2H),2.73-2.65(m,1H),2.17-2.14(m,1H),1.91-1.86(m,2H),1.83-1.74(m,1H),0.98(d,J＝6.8Hz,3H),0.87(d,J＝6.8Hz,3H)。
Comparative example 1: synthesis of hydrobromide salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate (Compound 3)
Figure BDA0002752340380000051
(S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate (compound 1) (200mg, 0.517mmol, 1eq) was dissolved in 5mL of THF, aqueous HBr (156.8mg, 0.776mmol, 1.5eq, 40 wt%) was added and stirred at 25 ℃ for 30min to precipitate a solid, which was filtered and the cake was dried to constant weight to give 193mg of (S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate hydrobromide salt (compound 3) as a yellow solid with a purity of 99% in 80% yield.
Molecular weight: m + H+＝388.2(ESI)。
1H-NMR(400MHz,DMSO-d6):δ：9.06(d,J＝2.8Hz,1H),9.03(d,J＝8.4Hz,1H),8.58(d,J＝8.8Hz,1H),7.90(dd,J＝4.0Hz,8.8Hz,1H),7.55(d,J＝8.8Hz,1H),6.20(d,J＝6.4Hz,1H),6.14(d,J＝6.4Hz,1H),4.36-4.33(m,1H),3.58-3.55(m,2H),2.70-2.63(m,1H),2.19-2.14(m,1H),1.92-1.87(m,2H),1.82-1.77(m,1H),0.95(d,J＝6.8Hz,3H),0.89(d,J＝6.8Hz,3H)。
Comparative example 2: synthesis of methanesulfonic acid salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylic acid ester (Compound 4)
Figure BDA0002752340380000061
(S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionyl-pyrrolidine-2-carboxylate (compound 1) (200mg, 0.517mmol, 1eq) was dissolved in 5mL of THF, methanesulfonic acid (50mg, 0.51mmol, 1.0eq) was added, and the mixture was stirred at 25 ℃ for 30min to precipitate a solid, which was filtered and the cake was dried to constant weight to give 135mg of (S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionyl-pyrrolidine-2-carboxylate methanesulfonate (compound 4) as a yellow solid with a purity of 99% and a yield of 54%.
Molecular weight: m + H+＝388.2(ESI)。
1H-NMR(400MHz,DMSO-d6):δ：9.09(d,J＝2.8Hz,1H),9.04(d,J＝8.4Hz,1H),8.58(d,J＝8.8Hz,1H),7.91(dd,J＝4.0Hz,8.8Hz,1H),7.56(d,J＝8.8Hz,1H),6.24(d,J＝6.4Hz,1H),6.14(d,J＝6.4Hz,1H),4.36-4.33(m,1H),3.58-3.55(m,2H),2.73-2.64(m,1H),2.19-2.14(m,1H),1.91-1.86(m,2H),1.83-1.76(m,1H),0.96(d,J＝6.8Hz,3H),0.90(d,J＝6.8Hz,3H)。
Comparative example 3: synthesis of hydrogen sulfate salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylic acid ester (Compound 5)
Figure BDA0002752340380000071
(S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionyl-pyrrolidine-2-carboxylate (compound 1) (200mg, 0.517mmol, 1eq) was dissolved in 5mL of THF, sulfuric acid (50mg, 0.517mmol, 1.0eq, 98 wt%) was added and stirred at 25 ℃ for 30min to precipitate a solid, which was filtered and the cake was dried to constant weight to give 135mg of (S) - (5-Nitro-quinolin-8-yloxy) methyl 1-isopropionyl-pyrrolidine-2-carboxylate hydrogen sulfate salt (compound 5) as a yellow solid with a purity of 99% and a yield of 44.6%.
Molecular weight: m + H+＝388.2(ESI)。
1H-NMR(400MHz,DMSO-d6):δ：9.08(d,J＝2.8Hz,1H),9.05(d,J＝8.4Hz,1H),8.55(d,J＝8.8Hz,1H),7.94(dd,J＝4.0Hz,8.8Hz,1H),7.55(d,J＝8.8Hz,1H),6.23(d,J＝6.4Hz,1H),6.15(d,J＝6.4Hz,1H),4.36-4.33(m,1H),3.58-3.55(m,2H),2.76-2.64(m,1H),2.24-2.14(m,1H),1.97-1.86(m,2H),1.85-1.77(m,1H),0.97(d,J＝6.8Hz,3H),0.90(d,J＝6.8Hz,3H)。
Test example 1 solubility test method and test results
Test method
I. In the following test methods, specific parameters of LC-MS/MS are as follows:
liquid chromatography system: shimadzu; mass spectrometry analysis: API 4000 instrument from AB Inc (canada) with ESI interface; column temperature: 25 ℃; sample introduction amount: 3. mu.L or 10. mu.L; a chromatographic column: ACE Ultra Core 2.5 Super C18(3.0 x 50mm) XP chromatography column in combination with a preguard chromatography column; mobile phase: 0.1 v% aqueous formic acid (A) and 0.1 v% acetonitrile formic acid (B); elution speed: 1 mL/min.
Time (min) 0.00 0.30 0.60 0.90 0.91 1.20
％B 5 5 100 100 5 5
The MS parameters were as follows: an ion source: turbo spraying; ionization model: ESI; the scanning type is as follows: MRM; collision gas: 10L/min; curtain gas: 30L/min; atomizing gas: 60L/min; auxiliary gas: 60L/min; temperature: 550 ℃; ion spray voltage: +5500V (positive MRM).
II. The specific operation steps of the test are as follows:
1. preparation of hydrochloric acid solution pH 1.2
Dissolving 7.65mL of HCl in ultrapure water, diluting to 1000mL with ultrapure water, and stirring.
2. preparation of acetate buffer solution of pH 4.5
(1) Preparation of 2mol/L CH3COOH
120.0g (114mL) of CH3Dissolving COOH in ultrapure water, and diluting with ultrapure water to 1000 mL.
(2)CH3Preparation of COONa
2.99g of CH3COONa is dissolved in ultrapure water and usedDiluting with ultrapure water to 1000 mL.
(3) 1000mL of CH3COONa and 14.0mL of 2mol/L CH3And uniformly mixing the COOH solution.
3. preparation of phosphate buffer solution of pH 6.8
(1) Preparation of 0.2mol/L KH2PO4Solutions of
Mixing 27.22g KH2PO4Dissolving in ultrapure water, and diluting to 1000mL with ultrapure water.
(2) Preparation of 0.2mol/L NaOH solution
8.00g of NaOH was dissolved in ultrapure water and diluted to 1000mL with ultrapure water.
(3) 250mL of 0.2mol/L KH2PO4The solution is mixed with 112mL of 0.2mol/L NaOH solution, diluted to 1000mL by ultrapure water and mixed evenly.
4. The test compound and the control compound diclofenac sodium (purchased from Sigma Chemical co., which is used to verify the accuracy and reliability of the test method) were weighed to measure solubility (for compound 2, three samples were weighed at one specific test condition, wherein 30mg of two samples were each placed in a 1.5mL glass vial as a test article, 3.0mg of a sample were placed in a 1.5mL glass vial as a standard article; for diclofenac sodium, compound 1, compound 3, compound 4, compound 5, each compound was also weighed at one specific test condition, about 1.0mg each, were each placed in three independent 1.5mL glass vials).
5. One vial was used as the standard and two other vials were used as the test article for each compound under the specified test conditions.
6. Each compound was placed in a 96-well rack in order, with standards placed in one 96-well rack and test items placed in the other 96-well rack.
7. To the test article, 1000 μ L of hydrochloric acid solution at pH 1.2, acetate buffer solution at pH 4.5, or phosphate buffer solution at pH 6.8 was added using a pipette gun, a stir bar was placed in each glass vial, and the glass vial was sealed using a PTFE/silica gel plug.
8. The test article was transferred to an Eppendorf Thermomixer Comfort plate shaker and shaken for 24 hours at 25 ℃ and 1100 RPM.
9. After 24 hours, the stir bar was removed using a large magnet, and the vial of test article was transferred to a filter plate using a pipette and filtered using a vacuum manifold. The filtrate was diluted 1000 times with acetonitrile to obtain test solution I. 100 μ L of test solution I was transferred to a new 96-well plate (designated as well plate I) along with 100 μ L of water for LC-MS/MS analysis. Dilution factor was varied according to solubility values and LC-MS signal response.
10. For the standard, a standard solution I (concentration of standard solution I is 3.0mg/mL for Compound 2; concentration of standard solution I is 1.0mg/mL for diclofenac sodium, Compound 1, Compound 3, Compound 4, Compound 5) was prepared, wherein the solvent was DMSO.
11. The standard vial was covered with a 96-well plate lid and the standard was placed on an Eppendorf Thermomixer Comfort plate shaker at 25 ℃ and 1100RPM for 5 minutes.
12. After 5 minutes, each compound was completely dissolved.
13. mu.L of the standard solution I was transferred to a new well plate A, and 495. mu.L of acetonitrile was added to the well plate to obtain a standard solution II. 50. mu.L of the standard solution II was transferred to a new well plate B, and 450. mu.L of acetonitrile was added to the well plate to obtain a standard solution III. 100 μ L of standard solution III was transferred to a new 96-well plate (designated as well plate II) along with 100 μ L of water for LC-MS/MS analysis. The concentration of the standard was adjusted according to the LC-MS signal response.
14. Well plate I and well plate II were placed in a well plate autosampler and evaluated by LC-MS/MS analysis at 4 ℃.
15. The solubility value of the test compound is calculated by the formula:
Figure BDA0002752340380000091
wherein S isTestingSolubility of the test Compound, ATestingTest solutions for LC-MS/MS analysis in step 9Peak area corresponding to liquid I, VTestingSample volume, DF, of test solution I to be subjected to LC-MS/MS analysis in step 9TestingDilution factor of the filtrate in step 9, CStandard of meritIs the concentration of the test compound in the standard solution I, AStandard of meritPeak area, V, corresponding to standard solution III sent to LC-MS/MS analysis in step 13Standard of referenceThe sample volume of standard solution III sent for LC-MS/MS analysis in step 13.
Figure BDA0002752340380000101
Note: q1: mass-to-charge ratio of parent ions; q2: the mass-to-charge ratio of the daughter ions; DP: de-clustering voltage; EP: an entrance voltage to direct and focus ions through a high voltage Q0 region; CE: collision energy; CXP: the collision cell exit voltage is used to focus and accelerate ions out of the Q2 region for Q3 region scanning and MS/MS.
Second, test results
Figure BDA0002752340380000102
From the above table, it can be seen that the hydrochloride salt of example 1 has much higher solubility than compound 1 of the prior art, as well as other salts, such as the hydrobromide, mesylate, bisulfate salts. Therefore, the hydrochloride is easier to absorb and has higher bioavailability, and is more beneficial to developing into medicaments suitable for human bodies.
While specific embodiments of the invention have been described above, it will be appreciated by those skilled in the art that this is by way of example only, and that the scope of the invention is defined by the appended claims. Various changes and modifications to these embodiments may be made by those skilled in the art without departing from the spirit and scope of the invention, and these changes and modifications are within the scope of the invention.

Claims (10)

  1. Hydrochloride of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate.
  2. 2. The hydrochloride salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate according to claim 1, having the formula:
    Figure FDA0002752340370000011
  3. 3. a process for the preparation of the hydrochloride salt of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylic acid ester according to claim 1 or 2, comprising the steps of:
    reacting the mixture of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate and organic solvent with a solution containing hydrochloric acid, and carrying out solid-liquid separation to obtain the compound.
  4. 4. The preparation method according to claim 3, wherein the organic solvent is one or more selected from tetrahydrofuran, methanol, ethanol, n-propanol, isopropanol, acetone and ethyl acetate, preferably tetrahydrofuran.
  5. 5. The production method according to claim 3 or 4, wherein the solvent in the hydrochloric acid-containing solution is one or more selected from the group consisting of ethyl acetate, water, methanol, ethanol, n-propanol, isopropanol and acetone, and preferably ethyl acetate.
  6. 6. The production method according to any one of claims 3 to 5, wherein the equivalent ratio of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate to hydrogen chloride in the hydrochloric acid-containing solution is 1:5 to 5:1, preferably 1:1.5 to 1:3, more preferably 1:1.5 to 1:2.5, still more preferably 1:2.
  7. 7. The production method according to any one of claims 3 to 6, wherein the reaction temperature is 10 to 30 ℃, preferably 20 to 30 ℃, and more preferably 25 ℃;
    and/or the reaction time is 10min-3h, preferably 10-60min, more preferably 25-35min, and even more preferably 30 min.
  8. 8. A pharmaceutical composition comprising the hydrochloride of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate according to claim 1 or 2, and a pharmaceutically acceptable carrier.
  9. 9. Use of the hydrochloride of (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropionylpyrrolidine-2-carboxylate according to claim 1 or 2, or the pharmaceutical composition according to claim 8, for the preparation of an anti-infective and/or anti-tumoral drug.
  10. 10. Use according to claim 9, the infection being a urinary tract infection, and/or the tumour being selected from bladder, prostate and renal cancers.
CN202011189484.0A 2020-10-30 2020-10-30 Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt Pending CN114437033A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011189484.0A CN114437033A (en) 2020-10-30 2020-10-30 Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011189484.0A CN114437033A (en) 2020-10-30 2020-10-30 Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt

Publications (1)

Publication Number Publication Date
CN114437033A true CN114437033A (en) 2022-05-06

Family

ID=81357123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011189484.0A Pending CN114437033A (en) 2020-10-30 2020-10-30 Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt

Country Status (1)

Country Link
CN (1) CN114437033A (en)

Similar Documents

Publication Publication Date Title
US10576084B2 (en) Salt of fused heterocyclic derivative and crystal thereof
EP3466958B1 (en) New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
EP3205653A1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
CN114736214B (en) Sesquiterpene derivative, pharmaceutical composition thereof, and preparation method and application thereof
CN112047893B (en) Gefitinib and salicylic acid co-crystal
US10551389B2 (en) Target binding molecules identified by kinetic target-guided synthesis
CN111825621A (en) Eutectic of olaparib and malonic acid and preparation method thereof
CN114989182A (en) Lipid compounds, compositions comprising the same and uses thereof
EP4279138A2 (en) Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof
EP2874628B1 (en) Salts and hydrates of antipsychotics
CN107043368B (en) Crystals of arylamine pyrimidine compounds and salts thereof
CN114437033A (en) Salt of nitroxoline prodrug, pharmaceutical composition containing salt, preparation method and application of salt
KR101208956B1 (en) Erlotinib dichloroacetate and anti-cancer agent comprising the same
CN102718675A (en) Agomelatine methanesulfonic acid complex and preparation method thereof
CN109153677B (en) Hydrochloride crystal form of PLX3397 and preparation method and application thereof
CN111393500A (en) Oleanolic acid derivative with conjugated diene structure C ring and preparation method and application thereof
WO2020053660A1 (en) Solid forms of a bet inhibitor
EP4092028A1 (en) Crystal of hypoxanthine compound
EP3964499A1 (en) Crystal forms of compound, preparation method therefor, pharmaceutical composition and application thereof
CN112174833B (en) Crystal form A of escargoline hydrochloride and preparation method thereof
CN111094313B (en) Crystalline form of idarubicin hydrochloride monohydrate
CN112174834B (en) Eptacrine hydrochloride B crystal form and preparation method thereof
CN115141136B (en) Co-crystals of tecan Wei Ruiyao and method for preparing same
EP3896071B1 (en) Crystalline form of propionamide derivative and preparation method therefor
EP4169915A1 (en) Crystalline form of compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064100

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination